From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.

ABSTRACT: Omics profiling significantly expanded the molecular landscape describing clinical phenotypes. Association analysis resulted in first diagnostic and prognostic biomarker signatures entering clinical utility. However, utilizing Omics for deepening our understanding of disease pathophysiology, and further including specific interference with drug mechanism of action on a molecular process level still sees limited added value in the clinical setting. We exemplify a computational workflow for expanding from statistics-based association analysis toward deriving molecular pathway and process models for characterizing phenotypes and drug mechanism of action. Interference analysis on the molecular model level allows identification of predictive biomarker candidates for testing drug response. We di

SUBMITTER: Heinzel A 

PROVIDER: S-EPMC4207010 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature